1 Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine 344, 783-792, doi:10.1056/NEJM200103153441101 (2001).
2 D Cameron, MJ Piccart-Gebhart, RD Gelber, et al.11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389 (2017), pp. 1195-1205
3 Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114, doi:10.1038/sj.onc.1203973 (2000).
4 Saez, R. et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12, 424-431, doi:10.1158/1078-0432.CCR-05-1807 (2006).
5 Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute 99, 628-638, doi:10.1093/jnci/djk134 (2007)
6 Nagy, P. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptinresistant, MUC4-expressing breast cancer cell line. Cancer Res 65, 473-482 (2005).
7 Wang, Y. et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4, 1214-1221, doi:10.1158/1535-7163.MCT-05-0048 (2005).
8 Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127, doi:10.1016/j.ccr.2004.06.022
9 Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature medicine 2000;6:443-6
10 Florian Reim, et al. Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cance Stem Cells. Cancer Res 2009; doi: 10.1158/0008-5472.CAN-09-0834
11 Scaltriti M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; doi: 10.1038/onc.2008.432.
12 Roca L, et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER- PACS 04 trial. Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587- x.
13 Tamura, K. et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann. Oncol.22, 1302–1307 (2011).
14 Thiery, J. et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nature immunology 12, 770-777, doi:10.1038/ni.2050 (2011).
15 Henkart, P. A., Berrebi, G. A., Takayama, H., Munger, W. E. & Sitkovsky, M. V. Biochemical and functional properties of serine esterases in acidic cytoplasmic granules of cytotoxic T lymphocytes. J Immunol 139, 2398-2405 (1987).
16 Breton, S. & Brown, D. Regulation of luminal acidification by the V-ATPase. Physiology (Bethesda) 28, 318-329, doi:10.1152/physiol.00007.2013 (2013).
17 Jalimarada, S. S., Ogando, D. G., Vithana, E. N. & Bonanno, J. A. Ion transport function of SLC4A11 in corneal endothelium. Invest Ophthalmol Vis Sci 54, 4330-4340, doi:10.1167/iovs.13- 11929 (2013).
18 Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 2010;37:1361-78
19 Adrain C, Murphy BM, Martin SJ. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. The Journal of biological chemistry 2005;280:4663-73
20 Martinvalet D, Dykxhoorn DM, Ferrini R, Lieberman J. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell 2008;133:681-92
21 Toei, M., Saum, R. & Forgac, M. Regulation and isoform function of the VATPases. Biochemistry 49, 4715–4723 (2010).
22 Arai, S. et al. Rotation mechanism of Enterococcus hirae V1-ATPase based on asymmetric crystal structures. Nature 493, 703-707, doi:10.1038/nature11778 (2013).
23 van Hille, B. et al. Heterogeneity of vacuolar H(+)-ATPase: differential expression of two human subunit B isoforms. Biochem J 303 ( Pt 1), 191-198 (1994).
24 Casey, J. R., Grinstein, S. & Orlowski, J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 11, 50-61, doi:10.1038/nrm2820 (2010)
論文の公開元へ
